Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
ESRX's Cash to Debt is ranked higher than
50% of the 52 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.63 vs. ESRX: 0.14 )
ESRX' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.14

Equity to Asset 0.37
ESRX's Equity to Asset is ranked higher than
72% of the 54 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. ESRX: 0.37 )
ESRX' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.55
Current: 0.37

0.13
0.55
Interest Coverage 6.18
ESRX's Interest Coverage is ranked higher than
61% of the 44 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.92 vs. ESRX: 6.18 )
ESRX' s 10-Year Interest Coverage Range
Min: 2.78   Max: 396
Current: 6.18

2.78
396
F-Score: 8
Z-Score: 3.23
M-Score: -2.28
WACC vs ROIC
6.89%
7.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 3.57
ESRX's Operating margin (%) is ranked higher than
78% of the 55 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.47 vs. ESRX: 3.57 )
ESRX' s 10-Year Operating margin (%) Range
Min: 2.76   Max: 6.06
Current: 3.57

2.76
6.06
Net-margin (%) 1.99
ESRX's Net-margin (%) is ranked higher than
76% of the 55 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.36 vs. ESRX: 1.99 )
ESRX' s 10-Year Net-margin (%) Range
Min: -0.13   Max: 3.53
Current: 1.99

-0.13
3.53
ROE (%) 9.62
ESRX's ROE (%) is ranked higher than
77% of the 52 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.53 vs. ESRX: 9.62 )
ESRX' s 10-Year ROE (%) Range
Min: -1.3   Max: 87.47
Current: 9.62

-1.3
87.47
ROA (%) 3.74
ESRX's ROA (%) is ranked higher than
76% of the 55 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.90 vs. ESRX: 3.74 )
ESRX' s 10-Year ROA (%) Range
Min: -0.38   Max: 14.42
Current: 3.74

-0.38
14.42
ROC (Joel Greenblatt) (%) 220.03
ESRX's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 53 Companies
in the Global Health Care Plans industry.

( Industry Median: 118.65 vs. ESRX: 220.03 )
ESRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.56   Max: 586.74
Current: 220.03

38.56
586.74
Revenue Growth (3Y)(%) 13.30
ESRX's Revenue Growth (3Y)(%) is ranked higher than
76% of the 51 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.30 vs. ESRX: 13.30 )
ESRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 12   Max: 69.8
Current: 13.3

12
69.8
EBITDA Growth (3Y)(%) 14.90
ESRX's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 46 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.60 vs. ESRX: 14.90 )
ESRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 3.4   Max: 87.6
Current: 14.9

3.4
87.6
EPS Growth (3Y)(%) 1.40
ESRX's EPS Growth (3Y)(%) is ranked higher than
72% of the 46 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.30 vs. ESRX: 1.40 )
ESRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 1.4   Max: 75.4
Current: 1.4

1.4
75.4
» ESRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ESRX Guru Trades in Q2 2014

First Pacific Advisors 2,838,100 sh (New)
Jim Simons 425,639 sh (New)
Charles Brandes 2,102,152 sh (New)
Steven Romick 0 sh (+9999.00%)
Joel Greenblatt 218,877 sh (+682.51%)
Ken Fisher 593,431 sh (+75.84%)
Dodge & Cox 17,874,930 sh (+54.28%)
Manning & Napier Advisors, Inc 3,238,540 sh (+50.74%)
HOTCHKIS & WILEY 1,918,200 sh (+50.52%)
Jeremy Grantham 18,244,782 sh (+45.26%)
Wallace Weitz 1,742,324 sh (+43.89%)
Glenn Greenberg 4,678,694 sh (+31.94%)
Paul Tudor Jones 8,380 sh (+21.45%)
Mario Gabelli 365,939 sh (+15.66%)
David Rolfe 5,526,574 sh (+11.43%)
Diamond Hill Capital 1,549,555 sh (+7.23%)
Vanguard Health Care Fund 3,265,000 sh (unchged)
Jean-Marie Eveillard 1,168 sh (unchged)
Louis Moore Bacon Sold Out
Leon Cooperman Sold Out
Jeff Auxier 77,896 sh (-0.31%)
John Keeley 30,958 sh (-5.84%)
Chris Davis 10,703,208 sh (-5.95%)
Pioneer Investments 2,806,675 sh (-8.35%)
Ruane Cunniff 5,031 sh (-11.03%)
Scott Black 129,139 sh (-22.86%)
Ray Dalio 37,654 sh (-62.30%)
» More
Q3 2014

ESRX Guru Trades in Q3 2014

Jeremy Grantham 25,535,124 sh (+39.96%)
Ray Dalio 50,162 sh (+33.22%)
First Pacific Advisors 3,441,000 sh (+21.24%)
Jim Simons 490,577 sh (+15.26%)
Vanguard Health Care Fund 3,621,200 sh (+10.91%)
Manning & Napier Advisors, Inc 3,583,120 sh (+10.64%)
David Rolfe 5,957,369 sh (+7.79%)
Charles Brandes 2,253,914 sh (+7.22%)
Diamond Hill Capital 1,657,313 sh (+6.95%)
Ruane Cunniff 5,372 sh (+6.78%)
Glenn Greenberg 4,982,726 sh (+6.50%)
Dodge & Cox 18,469,695 sh (+3.33%)
Wallace Weitz 1,776,907 sh (+1.98%)
Scott Black 129,479 sh (+0.26%)
Pioneer Investments 2,704,807 sh (unchged)
John Keeley 30,958 sh (unchged)
Jean-Marie Eveillard 1,168 sh (unchged)
Warren Buffett 449,489 sh (unchged)
Chris Davis 10,650,525 sh (-0.49%)
Jeff Auxier 75,725 sh (-2.79%)
HOTCHKIS & WILEY 1,851,500 sh (-3.48%)
Paul Tudor Jones 7,500 sh (-10.50%)
Ken Fisher 522,773 sh (-11.91%)
Mario Gabelli 247,614 sh (-32.33%)
Joel Greenblatt 48,001 sh (-78.07%)
» More
Q4 2014

ESRX Guru Trades in Q4 2014

Steven Romick 4,234,000 sh (New)
Ray Dalio 77,262 sh (+54.02%)
First Pacific Advisors 4,495,300 sh (+30.64%)
Chris Davis 13,002,699 sh (+22.09%)
Manning & Napier Advisors, Inc 4,162,823 sh (+16.18%)
David Rolfe 6,620,076 sh (+11.12%)
Dodge & Cox 19,248,979 sh (+4.22%)
Paul Tudor Jones 7,800 sh (+4.00%)
Ken Fisher 528,812 sh (+1.16%)
Diamond Hill Capital 1,673,172 sh (+0.96%)
John Keeley 30,998 sh (+0.13%)
Jean-Marie Eveillard 1,168 sh (unchged)
First Pacific Advisors 95,500 sh (unchged)
Warren Buffett Sold Out
Jeff Auxier 75,685 sh (-0.05%)
Pioneer Investments 2,667,725 sh (-1.37%)
Charles Brandes 2,207,728 sh (-2.05%)
Jeremy Grantham 24,246,330 sh (-5.05%)
Wallace Weitz 1,684,987 sh (-5.17%)
Ruane Cunniff 4,905 sh (-8.69%)
HOTCHKIS & WILEY 1,651,500 sh (-10.80%)
Scott Black 115,057 sh (-11.14%)
Vanguard Health Care Fund 3,206,500 sh (-11.45%)
Glenn Greenberg 4,088,652 sh (-17.94%)
Jim Simons 345,239 sh (-29.63%)
Mario Gabelli 134,879 sh (-45.53%)
Joel Greenblatt 25,788 sh (-46.28%)
» More
Q1 2015

ESRX Guru Trades in Q1 2015

Steven Romick 4,234,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Express Scripts Holding Co

Steven Romick Buys 7 US and International Stocks in Q4
Steven Romick (Trades, Portfolio), a value-minded investment manager of the FPA Crescent Fund (FPACX), found just as many attractive stocks outside the U.S. as within it in the fourth quarter. Read more...
Guru Focus Value Idea Contest: Get on board the earnings train of Express Scripts (ESRX)
Express Scripts is a good company according to Warren Buffett (Trades, Portfolio). We have learned that Mr. Buffett has a knack for buying quality companies. However, a good company is not always a good stock to buy. Is it still a good investment you may be asking? Should you get on board? Let’s roll up our sleeves and do a little digging into the company’s financials and background. Read more...
Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI
According to GuruFocus' list of 52-week highs, Illinois Tool Works Inc, Express Scripts, Teva Pharmaceutical Industries Ltd, Church & Dwight Company Inc, and SunTrust Banks Inc. have all reached their 52-week highs. Read more...
Wedgewood Partners' David Rolfe's Top Five Stocks
David Rolfe (Trades, Portfolio)’s Top Five Stocks Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.20
ESRX's P/E(ttm) is ranked higher than
67% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 31.90 vs. ESRX: 32.20 )
ESRX' s 10-Year P/E(ttm) Range
Min: 13.5   Max: 36.74
Current: 32.2

13.5
36.74
Forward P/E 14.25
ESRX's Forward P/E is ranked higher than
88% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 18.38 vs. ESRX: 14.25 )
N/A
PE(NRI) 32.70
ESRX's PE(NRI) is ranked higher than
78% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 31.90 vs. ESRX: 32.70 )
ESRX' s 10-Year PE(NRI) Range
Min: 13.46   Max: 35.82
Current: 32.7

13.46
35.82
P/B 3.20
ESRX's P/B is ranked higher than
58% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.12 vs. ESRX: 3.20 )
ESRX' s 10-Year P/B Range
Min: 1.85   Max: 31.66
Current: 3.2

1.85
31.66
P/S 0.64
ESRX's P/S is ranked higher than
65% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.67 vs. ESRX: 0.64 )
ESRX' s 10-Year P/S Range
Min: 0.33   Max: 1.08
Current: 0.64

0.33
1.08
PFCF 15.30
ESRX's PFCF is ranked higher than
77% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 20.04 vs. ESRX: 15.30 )
ESRX' s 10-Year PFCF Range
Min: 8.82   Max: 25.77
Current: 15.3

8.82
25.77
POCF 14.32
ESRX's POCF is ranked higher than
82% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.84 vs. ESRX: 14.32 )
ESRX' s 10-Year POCF Range
Min: 8.52   Max: 23.49
Current: 14.32

8.52
23.49
EV-to-EBIT 20.98
ESRX's EV-to-EBIT is ranked higher than
75% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 18.98 vs. ESRX: 20.98 )
ESRX' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 30.4
Current: 20.98

8.9
30.4
PEG 1.58
ESRX's PEG is ranked higher than
88% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.22 vs. ESRX: 1.58 )
ESRX' s 10-Year PEG Range
Min: 0.42   Max: 1.68
Current: 1.58

0.42
1.68
Shiller P/E 38.30
ESRX's Shiller P/E is ranked higher than
65% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 44.00 vs. ESRX: 38.30 )
ESRX' s 10-Year Shiller P/E Range
Min: 22.74   Max: 67.21
Current: 38.3

22.74
67.21
Current Ratio 0.62
ESRX's Current Ratio is ranked higher than
60% of the 45 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.30 vs. ESRX: 0.62 )
ESRX' s 10-Year Current Ratio Range
Min: 0.62   Max: 1.95
Current: 0.62

0.62
1.95
Quick Ratio 0.50
ESRX's Quick Ratio is ranked higher than
56% of the 45 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.77 vs. ESRX: 0.50 )
ESRX' s 10-Year Quick Ratio Range
Min: 0.5   Max: 1.82
Current: 0.5

0.5
1.82
Days Inventory 7.28
ESRX's Days Inventory is ranked higher than
88% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.00 vs. ESRX: 7.28 )
ESRX' s 10-Year Days Inventory Range
Min: 3.02   Max: 8.45
Current: 7.28

3.02
8.45
Days Sales Outstanding 21.63
ESRX's Days Sales Outstanding is ranked higher than
80% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 28.82 vs. ESRX: 21.63 )
ESRX' s 10-Year Days Sales Outstanding Range
Min: 13.97   Max: 78.43
Current: 21.63

13.97
78.43

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
ESRX's Price/DCF (Projected) is ranked higher than
92% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.50 vs. ESRX: 1.00 )
ESRX' s 10-Year Price/DCF (Projected) Range
Min: 0.93   Max: 7.15
Current: 1

0.93
7.15
Price/Median PS Value 1.00
ESRX's Price/Median PS Value is ranked higher than
85% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.30 vs. ESRX: 1.00 )
ESRX' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 2.34
Current: 1

0.51
2.34
Price/Peter Lynch Fair Value 1.60
ESRX's Price/Peter Lynch Fair Value is ranked higher than
92% of the 60 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.00 vs. ESRX: 1.60 )
ESRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.64   Max: 1.6
Current: 1.6

0.64
1.6
Earnings Yield (Greenblatt) 4.80
ESRX's Earnings Yield (Greenblatt) is ranked higher than
62% of the 55 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.90 vs. ESRX: 4.80 )
ESRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 11.3
Current: 4.8

3.3
11.3
Forward Rate of Return (Yacktman) 25.62
ESRX's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 41 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.31 vs. ESRX: 25.62 )
ESRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 24.6   Max: 38
Current: 25.62

24.6
38

Business Description

Industry: Health Care Plans » Health Care Plans
Compare:UNH, WLP, HUM, AET, CI » details
Traded in other countries:4XS.Germany, ESRX.Switzerland,
Express Scripts Holding Co was incorporated in the State of Delaware on July 15, 2011 as Aristotle Holding, Inc. It operates as a Pharmacy benefit management in North America. It includes HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans and government health programs. It helps health benefit providers address access and affordability concerns resulting from rising drug costs while helping to improve healthcare outcomes. It works with clients, manufacturers, pharmacists and physicians to increase efficiency in the drug distribution chain, to manage costs in the pharmacy benefit and to improve members' health outcomes and satisfaction. The Company supports healthier outcomes by applying science to health decisions. It offers solutions in four areas namely benefit choices, drug choices, pharmacy choices and health choices. Health Decision ScienceSM is the Company's approach to understand and improve the decisions that impact clinical and financial outcomes and applies principles and advanced knowledge from three disciplines: behavioral sciences, clinical specialization and actionable data. These disciplines form a powerful combination that seeks to increase the likelihood of healthier decisions and healthier outcomes. Consumerology(r), or the advanced application of the behavioral sciences to healthcare, optimizes decision mechanisms and helps make decisions easier. Therapeutic Resource CentersSM gives patients access to specialist pharmacists and nurses to close gaps in care. It has organized its operations into two business segments based on products and services offered PBM and Business Operations. The Company's PBM segment consists services such as the retail network pharmacy administration, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management, clinical solutions to improve health outcomes, such as adherence, case coordination and personalized medicine, flexible array of Medicare Part D, Medicaid and Health Insurance Marketplace offerings to support clients' benefits, specialty pharmacy, including the distribution of fertility pharmaceuticals requiring special handling or packaging, administration of a group purchasing organization and consumer health and drug information. The Business Operations segment consists of distribution of pharmaceuticals and medical supplies to providers and clinics and scientific evidence to guide the safe, effective and affordable use of medicines. The Company is subject to federal and state laws and regulations.
» More Articles for ESRX

Headlines

Articles On GuruFocus.com
Analyzing Chris Davis' Top Holdings Apr 14 2015 
Charles Brandes' Top Growth Stocks Apr 07 2015 
CVS Health Corporation (CVS) Dividend Stock Analysis Apr 07 2015 
UnitedHealth Group Is Ready For A Huge Pharmacy Deal Apr 06 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Vanguard Health Care Fund's Undervalued Stocks Apr 03 2015 
UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 
Why Express Scripts is a Good Buy at Current Levels Apr 01 2015 
Aetna: Solid Prospects in a Volatile Environment Mar 31 2015 
Analyzing Steven Romick's New Buys: Express Scripts (ESRX) Mar 19 2015 


More From Other Websites
Why Walgreens Won't Buy A PBM Anytime Soon Apr 18 2015
AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog Apr 16 2015
Why CVS Health And McKesson May Be Good Stock Picks Apr 16 2015
Exciting time for drug breakthroughs: Merck CEO Apr 16 2015
UnitedHealthcare Q1 earnings beats Street Apr 16 2015
Will Walgreens make a run for Express Scripts? Apr 10 2015
Express Scripts, Silicon Motion, Apogee Break Out Apr 09 2015
Express Scripts climbs as Walgreens states interest in deals Apr 09 2015
Express Scripts climbs as Walgreens states interest in deals Apr 09 2015
Stocks Wobble At Starting Line; Express Scripts Up, Altera Dips Apr 09 2015
Express Scripts Holding Company Announces First Quarter 2015 Earnings Conference Call Apr 08 2015
Express Scripts Holding Company Announces First Quarter 2015 Earnings Conference Call Apr 08 2015
After Rising 80%, UnitedHealth Looks Pricey Apr 03 2015
The Zacks Analyst Blog Highlights: UnitedHealth Group, Catamaran, CVS Health, Express Scripts and... Apr 01 2015
SIOR chapter announces deals of the year for western Pennsylvania Apr 01 2015
Express Scripts (ESRX) Stock Is Up Today on Heavy Trading Volume Mar 31 2015
Breakout time for Express Scripts? Mar 31 2015
UnitedHealth Arm to Boost Pharmacy Benefits with Catamaran - Analyst Blog Mar 31 2015
Post-UNH Deal, Spotlight on Pharmacy Benefit Stocks - Analyst Blog Mar 31 2015
[$$] UnitedHealth to Buy Catamaran for $12.8 Billion in Cash Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK